Cabaletta Bio

Cabaletta Bio is a Nasdaq-listed clinical-stage biotechnology company developing engineered T cell therapies for autoimmune diseases, including its lead CD19-CAR T candidate CABA-201. Cabaletta's CAR T candidate Rese-cel was manufactured on Cellares' Cell Shuttle platform, and the two companies signed a ten-year commercial supply agreement in April 2026.

Company Facts

• Headquarters: Philadelphia, United States
• Founded: 2017
• Type: public
• Website: https://www.cabalettabio.com
• Industries: Biopharmaceuticals, Cell Therapy, Autoimmune Disease